The second hearing aid of its type to be approved by the US Food and Drug Administration (FDA) for direct-to-consumer sales in the US is taking its first steps towards the future US over-the-counter (OTC) sales channel.
Australian-based Nuheara, which has so far mostly concerned itself with the market for earbuds with different degrees of hearing enhancing technology, has recently begun a clinical trial to test the safety and effectiveness of its newly developed series of hearing aid products, it writes in a press release. In August, the company aired its plans to have its product series Iqbuds clinically validated and approved.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.